Microbot Medical Expands LIBERTY Sales Footprint, Targets Positive Gross Margins in 2027

Key Points for MBOT Investors

• Microbot is on track to have 12 U.S. sales territories by the end of 2026 and has hired three Area Sales Managers and one Regional Sales Director.
• Its first California customer extends its reach into the western U.S., while the company is also expanding in North Carolina.
• Microbot is engaging hospital Value Analysis Committees earlier in the sales process; based on its experience, that review takes four to six months.
• A second manufacturing line and more efficient processes are expected to help the company achieve positive gross margins in 2027.
• Microbot expects potential CE mark approval in late 2026 or early 2027, while pursuing opportunities in parts of Asia and the Middle East.

Microbot Medical (NASDAQ: MBOT) is expanding the U.S. sales footprint for its LIBERTY Endovascular Robotic System and has secured its first customer in California. At a September 24, 2026, analyst meeting, the company also outlined changes to its hospital sales strategy, manufacturing plans and international expansion efforts.

California Customer Marks Western U.S. Sales Expansion

Microbot said it is broadening its commercial presence to support its first customer in California and further expansion in North Carolina. The company expects to reach 12 sales territories by year-end, supported by its recent sales hires.

For investors, the California customer is a sign of geographic progress, but the announcement does not disclose the size of the order, associated revenue or the number of LIBERTY procedures expected.

Earlier Hospital Reviews Could Shape LIBERTY Adoption

Microbot has adjusted its sales strategy to engage Value Analysis Committees earlier. These hospital reviews have taken four to six months in the company’s experience, and Microbot is now engaged with committees at multiple health systems.

The company believes earlier engagement could help it gain access across systems with multiple hospitals. That remains a commercial goal rather than a confirmed rollout: investors will need to watch whether the reviews lead to purchasing decisions and broader use.

Manufacturing Changes Target Positive Gross Margins in 2027

Microbot plans to add a second manufacturing line and adopt more efficient production processes. It expects those steps to result in positive gross margins in 2027.

This is an important profitability milestone for a commercial-stage device company, though the announcement does not provide current gross margins, production costs or a timeline for bringing the second line online.

International Growth Depends on Regulatory Progress

Microbot said potential expansion into certain markets in Asia and the Middle East is in advanced stages. It is also working with regulatory bodies toward a CE mark, which it expects in late 2026 or early 2027.

LIBERTY is an FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. It is designed to support precise vascular navigation while aiming to reduce clinicians’ radiation exposure and physical strain. For MBOT investors, the next indicators of commercial traction will be customer additions, hospital-system approvals, manufacturing progress and regulatory milestones, not sales-territory growth alone.